Samsung Medical Center
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- 501
- Market Cap
- -
Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 240
- Registration Number
- NCT01470443
- Locations
- π°π·
Samsung medical Center, Seoul, Korea, Republic of
Pharmacogenomic Study (Adjuvant Chemotherapy)
Completed
- Conditions
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 792
- Registration Number
- NCT01470404
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Samsung Medical Center
- Registration Number
- NCT01470742
- Locations
- π°π·
Samsung medical Center, Seoul, Korea, Republic of
Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT01469598
- Locations
- π°π·
Samsung medical Center, Seoul, Korea, Republic of
A Trial of JX-594 in Refractory Colorectal Carcinoma
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT01469611
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Study of LV5FU2 Versus FOLFOX for Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2011-11-16
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 68
- Registration Number
- NCT01467921
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 80
- Registration Number
- NCT01466543
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Partial Posterior Hyaloidectomy in Macular Surgery
Phase 1
Completed
- Conditions
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2011-10-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT01454466
Clinical Outcomes of Endoscopic Resection for Treating WHYX Lesion
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-10-13
- Last Posted Date
- 2011-10-13
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 872
- Registration Number
- NCT01451034
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Endoscopic Ultrasound-guided Fine Needle Aspiration of Solid Masses: Histological and Immunohistochemical Evaluation
- First Posted Date
- 2011-09-20
- Last Posted Date
- 2011-09-20
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 116
- Registration Number
- NCT01437410
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Β© Copyright 2024. All Rights Reserved by MedPath